Stockreport

FDA Clears Flex Pharma's FLX-787 to Commence US Phase 2 Trial in ALS Under IND

FLEX PHARMA  (FLKS) 
Last flex pharma earnings: 8/1 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.flex-pharma.com/investor-overview
PDF BOSTON--(BUSINESS WIRE)-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), focused on developing treatments for cramps and spas [Read more]